Market Access Views & Analysis

Views & Analysis

The biggest challenges in rare disease drug development – and how the industry is fighting them

The biggest challenges facing rare disease pharma – and how ...

As Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers and ask whether the future is bright or bleak for these difficult conditions.

Views & Analysis

UK leaders: Takeda’s Jon Neal

In the first of a new series where we talk to GMs of UK pharma divisions, managing director for Takeda UK & Ireland, Jon Neal, tells us about the Shire acquisition, rare diseases, a

Views & Analysis

Simple steps to better communicate NHS medicines spend

Leela Barham says that there’s a communication problem when it comes to one of the most important and basic statistics about medicines in the UK: how much the UK spends on them.

Views & Analysis

Q&A--Fortress-Biotech-on-breathing-new-life-into-abandoned-drugs

Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new l...

One downside of the explosion in our knowledge about potential drug targets is that many promising candidates are getting left on the backburner.

Views & Analysis

3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

Views & Analysis